Abstract Body

Background: Whereas the incidence of HIV-associated dementia (HAD) has declined due to successful anti-retrovirals treatment, prevalence of milder forms of HAD, which include asymptomatic neurocognitive impairment (ANI) and minor neurocognitive disorder (MND) has increased. Both ANI and MND are part of what is known as HIV-associated neurocognitive disorders (HAND). However, the molecular mechanisms explaining regulation of HIV activation in the brain remain ill-defined. The Nurr1/CoREST transrepression pathway has been recently described as a regulator of glial cells response to brain inflammation by limiting over-reactivation of NF-κB-dependent pro-inflammatory genes. Methodology: Microglial cell culture, pharmacological inhibition, shRNA-mediated knockdown, and chromatin immunoprecipitation/sequencing. Results: We report here that, unlike in latently-infected T-cells, in latently-infected microglial cells (CHME-5/HIV), HIV is induced by pharmacological inhibitors of the CoREST complex chromatin-modifying enzymes LSD1 and G9a/GLP; these inhibitors also sensitized CHME-5/HIV cells for LPS or IL-1β-mediated HIV reactivation. shRNA-mediated knockdown of Nurr1, LSD1, or CoREST yielded similar results. Chromatin immunoprecipitation analysis followed by high throughput next generation sequencing revealed that upon microglia treatment with TNFα, the nuclear receptor co-repressor 2 (NCOR2/SMRT), which strongly interacts with Nurr1 to facilitate transrepression, is present at the HIV promoter before activation, then recruited at the earliest time points, and then its presence fluctuates over time. Likewise, Nurr1, CoREST, LSD1, and G9a are recruited to the HIV promoter, changing the epigenetic signature (lower H3K4Me/higher H3K9Me2). The repressor role of these proteins in regulating HIV emergence from latency has been confirmed by unbiased shRNA screens for factors involved in maintaining HIV silenced in latently-infected microglial cells. Conclusions: Our data indicate that the NCOR2-Nurr1-CoREST axis plays a role in preventing HIV over-reactivation in microglial cells, and studying this mechanism in detail may provide therapeutic targets for the treatment of HAND.